Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies

BACKGROUND: The ability to discriminate indolent from clinically significant prostate cancer (PC) at the initial biopsy remains a challenge. The ExoDx Prostate (IntelliScore) (EPI) test is a noninvasive liquid biopsy that quantifies three RNA targets in urine exosomes. The EPI test stratifies patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Margolis, Erik, Brown, Gordon, Partin, Alan, Carter, Ballentine, McKiernan, James, Tutrone, Ronald, Torkler, Phillipp, Fischer, Christian, Tadigotla, Vasisht, Noerholm, Mikkel, Donovan, Michael J., Skog, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184274/
https://www.ncbi.nlm.nih.gov/pubmed/34593984
http://dx.doi.org/10.1038/s41391-021-00456-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184274/
https://www.ncbi.nlm.nih.gov/pubmed/34593984
http://dx.doi.org/10.1038/s41391-021-00456-8

Ejemplares similares